BACKGROUND: Outcome of low-grade gliomas (LGG) is highly variable and depends on clinical factors, molecular features, and treatments. Molecular characterization of LGG has improved in recent years and is now essential for diagnosis and treatment of these diseases. Clinical factors, such as age and the extent of surgery, were considered prognostic for decades, but now their role is less clear. METHODS: We retrospectively evaluated all adult LGG patients from our data warehouse who received surgery and had sufficient tissue to assess biomarkers characterization. IDH1/2 mutation, MGMT methylation and 1p/19 codeletion were assessed on formalin-fixed paraffin-embedded samples. RESULTS: 204 consecutive LGG were included. Median follow up was 78.6 months. The mean age was 40 (range:18-72), 111 patients (54.4%) were <40 years of age; 27 patients (13.2%) underwent biopsy, 123 patients (60.3%) partial resection, 54 patients (26.5%) complete resection. Twenty-eight patients (13.7%) were considered low risk according to RTOG (<40 years with complete resection). IDH mutation was found in 82.8% of patients. 1p/19q codeletion was found in 46.4% of patients, MGMT methylation in 65.2% of patients. Median survival was 211.0 months (95%CI:190.4-231.6) in low risk patients, and 145.3 months (95%CI: 135.1-155.6) in high risk patients (P=0.010). Median survival for patients with IDH 1/2 mutation was 164.0 months (95%CI:112.1-215.9) and 77.1 months in patients IDH 1/2 wild type (95%CI:15.4-138.9, P<0.001). Multivariate analysis showed that low risk according to RTOG (P=0.006), IDH 1/2 mutation (P<0.001) and 1p/19q codeletion (P=0.035) were significantly correlated with overall survival. MGMT methylation was not significant. CONCLUSIONS: The management of LGG is complex. Both molecular profiling and clinical risk assessment are necessary for the decision making process in these rare tumors.
ACTR-02. AN MULTIVARIATE ANALYSIS FOR PROGNOSTIC SURVIVAL OF 121 ELDERLY PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA
Hui Ouyang; Department of Neurosurgery, Southern Medical University, Nanfang Hospital, Guangzhou, China OBJECTIVE: To verify the role and impact of extent of resection on elderly patients with newly diagnosed GBM for survival. METHODS: The medical data like gender, age, symptom, symptom duration, preoperative Karnofsky performance status (KPS), preoperative Charlson combidity index [21] , preoperative Performance status of ECOG (PS), preoperative American Society of Anesthesiologists index (ASA), preoperative comorbid disease, tumor location, tumor size, extent of resection (EOR), adjuvant therapy, interval of adjuvant-treatment administration after operation and immunohistochemistry, duration for anesthesia and surgery, and vol- OBJECTIVES: To establish the safety and feasibility of rapidly infusing rituximab over 90 minutes in patients with primary CNS lymphoma. BACKGROUND: Administering rituximab at standard rate is meant to minimize infusion reactions though results in long infusion times with first doses averaging six hours and subsequent doses four hours. In a subset of patients with systemic B-cell mediated diseases, rapidly infusing subsequent rituximab doses over 90 minutes is safe, feasible, decreases healthcare costs, and improves patient satisfaction. We initiated a pilot study to determine if rapid infusion of rituximab is safe in patients with CNS lymphoma. METH-ODS: We reviewed all patients with CNS lymphoma who received rapid rituximab infusions from January 2016 to June 2016. Pilot inclusion criteria include age ≥18 years, tolerated ≥1 previous rituximab infusions at standard rate without reaction, and did not receive concurrent chemotherapy on day of infusion. Concomitant corticosteroids to control disease related neurologic symptoms were allowed. The primary endpoint was incidence of infusion reactions. RESULTS: Five out of nine patients screened for rapid rituximab infusion met criteria and a total of 21 infusions were administered. Patients had a median age of 61 years (range 45-63 years) and 4 were female. All patients received rituximab dosed at 500 mg/m2 for diagnosis of primary CNS lymphoma. Pre-medication consisted of acetaminophen and diphenhydramine. Prior to first rapid infusion, four patients received one standard infusion and one patient had received three. None of the five patients experienced a reaction during any rapid infusion. Two patients were on dexamethasone 2mg daily during their first rapid infusion. Steroids were not administered with any other infusion. CONCLUSION: Rapid administration of rituximab was safe and feasible for patients with primary CNS lymphoma.
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BACKGROUND: The benefit of adding chemotherapy to radiotherapy (RT) in newly diagnosed anaplastic glioma without 1p/19q co-deletion is unknown. The CATNON trial investigated the impact of adjuvant and/or concurrent chemotherapy with temozolomide (TMZ) in these tumors. METHODS: Eligible were patients with newly diagnosed WHO grade III glioma without 1p/19q co-deletion, ≥ 18 years, and WHO performance status (PS) 0-2. All patients received RT 59.4 Gy in 33 fractions, and in a 2 x 2 factorial design were randomized to i. RT alone; ii. RT with concurrent daily 75 mg/m2 TMZ; iii. RT followed with 12 cycles of 150-200 mg/m2 adjuvant TMZ day 1-5/4 weeks; or iv. RT with both concurrent and 12 cycles of adjuvant TMZ. Stratification factors included O6-methyl-guanine DNA methyltransferase (MGMT) promoter methylation and PS. Primary endpoint was overall survival (OS). 748 patients and 534 events were needed to detect a HR reduction of 0.775 for both concurrent and adjuvant TMZ. An interim analysis was foreseen after 219 events (41%), and required a p value of 0.0084 for rejecting the Null hypothesis of no OS difference. RESULTS: Between Dec 2007 and Aug 2015 748 patients were randomized. On Oct 6, 2015 the interim analysis was conducted based on 221 events (median follow-up: 27 months). The analysis showed a HR reduction for OS of 0.645 (95% CI 0.450, 0.926; p= 0.0014) after adjuvant TMZ (arms iii and iv). MGMT status could be determined in 74% of patients, and was found methylated in 42% of them. MGMT methylation was prognostic for OS (HR 0.54, 95% CI 0.38, 0.77; p= 0.001), but at this stage did not predict improved outcome to adjuvant TMZ. For progression free survival (PFS), the risk adjusted HR of adjuvant TMZ was 0.586 (95% CI 0.472, 0.727; p < 0.0001). OBJECTIVE: The aim of this phase I/II study was to examine the efficacy and toxicity profile of TMZ plus nimustine (ACNU), which is one of nitrosoureas for malignant gliomas. METHODS: Patients who had received a standard radiotherapy with one or two previous chemo-regimens were enrolled on the phase I/II study. In phase I, the maximum-tolerated dose (MTD) by TMZ (150mg/m2/day) (Day1-5) plus various doses of ACNU (30, 35, 40 ,45 mg/m2/day) (Day15) per 4 weeks was defined on a standard 3+3 design. In phase II including the cohort 3 (MTD) of phase I, these therapeutic activity and safety of this regimen were evaluated. RESULTS: Fortynine patients were enrolled. Their median age was 50 years-old. Eighty percent of patients (39/49 cases) had a KPS of 70-100. These histologies were 73% (36 cases) glioblastoma, 22% (11 cases) anaplastic astrocytoma, 4% (2 cases) anaplastic oligodendroglioma. In phase I, 15 patients were treated at four cohorts by TMZ plus ACNU. MTD was TMZ (150/mg/m2) plus ACNU (40mg/m2). In phase II, 40 patients were treated at the dose of cohort 3 (MTD). Thirty-five percent of patients (14 of 40) experienced grade 3 or 4 toxicities, mainly hematologic. The overall response rate was 11% (4/37). Sixty-eight percent (25/37) had stable disease. Twenty-two percent (8/37) showed progression. Progression free survival (PFS) at 6 and 12 month were 24% (95%CI, 12-35%) and 8% (95%CI, 4-15%). Median PFS was 13 months (95%CI, 9.2-17.2months). Overall survival (OS) at 6 and 12 were 78% (95%CI, 67-89%) and 49% (95%CI, 33-57%). Median OS was 11.8 months (95%CI, 8.2-14.5months). CONCLUSION: This phase I/II study showed a moderate toxicity in hematology and may has a promising efficacy in OS, without inferiority in PFS, comparing with other studies. This regimen could be an option for recurrent malignant gliomas, though further clinical studies are warranted. and spreads in actively proliferating cancer cells. Subsequent oral administration of the extended-release antifungal drug 5-fluorocytosine (Toca FC) results in production of 5-fluorouracil (5-FU), via the CD enzyme, within infected cells. 5-FU kills cancer cells and myeloid derived suppressor cells and activates the immune system against cancer, leading to durable antitumor immune responses in animal models. This sequence of events is amplified with multiple cycles of 5-fluorocytosine. Clinical data from 2 ongoing phase 1 trials (NCT01156584, NCT01470794) in recurrent high grade glioma (HGG) are consistent with this mechanism of action, and show a favorable safety profile and extended survival compared to historical controls. Standard of care for newly diagnosed HGG includes maximum safe extent resection and chemoradiation with temozolomide (TMZ). A Phase 1b study, treating newly diagnosed HGG subjects with Toca 511 and Toca FC added to standard of care (SOC), will examine safety and overall survival (OS) compared to historical controls. Based on the high unmet need for effective therapies and the additive preclinical efficacy demonstrated with Toca 511 and radiation or TMZ, this multi-center, open-label study will enroll approximately 24 subjects with newly diagnosed HGG prior to tissue diagnosis or definitive initial surgical resection. Subjects will be treated with Toca 511 and dose escalation of Toca FC added to SOC. The primary objective is to establish the recommended Phase 2 dose of Toca FC and secondary objectives are to evaluate the safety, tolerability and preliminary efficacy as measured by OS and progression-free survival. Evidence for immunologic mechanisms of disease control and molecular profiling of resected tumor samples will be evaluated to identify potential biomarkers for treatmentrelated response.
ACTR-05. PHASE I/II STUDY OF TEMOZOLOMIDE PLUS NIMUSTINE CHEMOTHERAPY FOR RECURRENT MALIGNANT GLIOMAS: KYOTO NEURO-ONCOLOGY GROUP
ACTR
